Na Uy - Tiếng Na Uy - Statens legemiddelverk

krka, d.d. novo mesto - metoprololsuksinat - depottablett - 25 mg

Na Uy - Tiếng Na Uy - Statens legemiddelverk

krka, d.d. novo mesto - metoprololsuksinat - depottablett - 50 mg

Na Uy - Tiếng Na Uy - Statens legemiddelverk

krka, d.d. novo mesto - metoprololsuksinat - depottablett - 100 mg

Na Uy - Tiếng Na Uy - Statens legemiddelverk

s.a.l.f s.p.a. laboratorio farmacologico - ketorolaktrometamol - injeksjonsvæske, oppløsning - 30 mg/ ml

Na Uy - Tiếng Na Uy - Statens legemiddelverk

macure pharma aps - metoprololtartrat - injeksjonsvæske, oppløsning - 1 mg/ ml

Liên Minh Châu Âu - Tiếng Na Uy - EMA (European Medicines Agency)

mylan ire healthcare limited - pretomanid - tuberkulose, multidrug-resistent - antimykobakterielle - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.

Na Uy - Tiếng Na Uy - Statens legemiddelverk

macure pharma aps - amikacinsulfat - injeksjonsvæske, oppløsning - 250 mg/ ml

Na Uy - Tiếng Na Uy - Statens legemiddelverk

krka, d.d. novo mesto - metoprololsuksinat - depottablett - 200 mg

Liên Minh Châu Âu - Tiếng Na Uy - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft-avvisning - immunsuppressive - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Liên Minh Châu Âu - Tiếng Na Uy - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - multippel sklerose, relapsing-remitting - immunsuppressive - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).